Melanoma: Clinical Trials

Showing 35 trials
Title Investigatorsort icon
A Phase I Study of an mRNA-Modified Dendritic Cell Vaccine in Patients with Melanoma
[Protocol 10-229]
Young, James, MD
A Study of the Biologic Effects of BMS-936558 in Patients with Inoperable or Metastatic Melanoma
[Protocol 12-231]
Wolchok, Jedd, MD, PhD
A Phase Ib Study of MDX-1106 (BMS-936558) in Combination with Ipilimumab (BMS-734016) in Patients with Unresectable Stage III or Stage IV Malignant Melanoma
[Protocol 09-155]
Wolchok, Jedd, MD, PhD
A Phase I Study of Lirilumab plus Nivolumab in Patients with Advanced Solid Tumors
[Protocol 12-224]
Segal, Neil, MD, PhD
A Phase I Study of MEDI4736 in Patients with Advanced Solid Tumors
[Protocol 12-179]
Segal, Neil, MD, PhD
A Phase I Study of BMS-986015 with Ipilimumab in Patients with Advanced Non-Small Cell Lung Cancer, Prostate Cancer, or Melanoma
[Protocol 12-283]
Rizvi, Naiyer, MD
A Phase I/IIA Study of Dabrafenib in Children with Advanced BRAF Mutation-Positive Solid Tumors
[Protocol 13-016]
Pratilas, Christine, MD
A Phase I Study of Vemurafenib in Adolescents with Inoperable Stage IIIC/IV Melanoma with V600 BRAF Mutations
Newly Diagnosed & Relapsed/Refractory
[Protocol 11-198]
Pratilas, Christine, MD
A Phase I Study of the NY-ESO-1 Vaccine plus Ipilimumab in Patients with Inoperable or Metastatic Melanoma
[Protocol 12-253]
Postow, Michael, MD
A Phase III Study of MEK162 versus Dacarbazine in Patients with Inoperable or Metastatic Melanomas with NRAS Q61 Mutations: The NEMO Trial
[Protocol 13-083]
Postow, Michael, MD
A Phase II Study of LEE011 plus LGX818 in Patients with BRAF-Mutant Melanoma
[Protocol 13-097]
Postow, Michael, MD
A Phase II Study of LEE011 plus MEK162 in Patients with NRAS-Mutant Melanoma
[Protocol 13-102]
Postow, Michael, MD
A Phase II Study of Nivolumab plus Ipilimumab versus Ipilimumab Alone in Patients with Previously Untreated Inoperable or Metastatic Melanoma
[Protocol 13-169]
Postow, Michael, MD
A Phase II Study of LGX818 plus a Second Investigational Drug in Patients with Locally Advanced or Metastatic Melanoma that Continued to Grow on LGX818 Alone
[Protocol 13-233]
Postow, Michael, MD
Expanded Access to MK-3475 for Patients with Metastatic Melanoma with Few to No Treatment Options
[Protocol 14-093]
Postow, Michael, MD
A Phase II Study of Dasatinib in Patients with Inoperable Locally Advanced or Metastatic c-KIT-Positive Acral or Mucosal Melanoma
[Protocol 13-100]
Leitao, Mario, MD
An Evaluation of Perceptions and Quality of Life Among Patients Receiving Ipilimumab for Melanoma
[Protocol 11-184]
Hay, Jennifer, PhD
A Phase II Study of Ipilimumab in Children and Adolescents with Stage III/IV Inoperable Melanoma
Newly Diagnosed & Relapsed/Refractory
[Protocol 13-043]
Dunkel, Ira, MD
A Phase III Study of BMS-936558 (Nivolumab) versus Standard Chemotherapy in Patients with Advanced Melanoma that Progressed Despite Anti-CTLA-4 Therapy
[Protocol 12-254]
D'Angelo, Sandra, MD
A Phase II Study of LGX818 Given in a Pulsatile Schedule to Patients with Stage III or IV Melanoma with a BRAF Mutation
[Protocol 13-053]
Chapman, Paul, MD
A Phase II Clinical Trial of Trametinib plus GSK2141795 in Patients with Melanoma Containing a Normal BRAF Gene
[Protocol 13-258]
Chapman, Paul, MD
A Phase II Study of Dabrafenib After Surgery in Patients with BRAF V600 Mutation-Positive Stage IIIC Melanoma
[Protocol 12-124]
Chapman, Paul, MD
A Phase III Study of Vemurafenib in Patients with Surgically Removed BRAF-Mutant Melanoma Who Have a High Risk of Recurrence
[Protocol 12-166]
Chapman, Paul, MD
A Phase II Study of Trametinib with and without GSK2141795 in Patients with Advanced Uveal Melanoma
[Protocol 13-144]
Carvajal, Richard, MD
A Phase Ib Study of AEB071 and MEK162 in Patients with Advanced Uveal Melanoma
[Protocol 13-172]
Carvajal, Richard, MD
A Phase I Study of BVD-523 in Patients with Advanced Cancers
[Protocol 13-254]
Carvajal, Richard, MD
A Phase II Study of Dacarbazine with and without Selumetinib to Treat Metastatic Uveal Melanoma
[Protocol 14-033]
Carvajal, Richard, MD
A Phase II Study of RAD001 (Everolimus) and Pasireotide (SOM230)) in Patients with Advanced Uveal Melanoma
[Protocol 10-123]
Carvajal, Richard, MD
A Phase I Study of AEB071 in Patients with Metastatic Uveal Melanoma
[Protocol 11-167]
Carvajal, Richard, MD
A Phase II Study of Vorinostat for Metastatic Uveal Melanoma
[Protocol 12-027]
Carvajal, Richard, MD
A Phase I Study of Dabrafenib and Ipilimumab with and without Trametinib for Advanced Melanoma
[Protocol 12-285]
Callahan, Margaret, MD, PhD
Targeted Silica Nanoparticles for Image-Guided Sentinel Lymph Node Mapping During Surgery in Patients with Melanoma of the Head and Neck
Newly Diagnosed & Relapsed/Refractory
[Protocol 13-249]
Bradbury, Michelle, MD
A Phase III Study of Surgery Followed by Radiation Therapy or Observation in Patients with Neurotropic Melanoma of the Head and Neck
[Protocol 13-248]
Barker, Christopher, MD
A Phase I Study of AM0010 in Patients with Advanced Solid Tumors
[Protocol 13-224]
Autio, Karen, MD
A Phase II Study of Ipilimumab Plus Isolated Limb Infusion with Melphalan and Dactinomycin to Treat Advanced Unresectable Melanoma of the Extremity
[Protocol 10-101]
Ariyan, Charlotte, MD